<div id="readability-page-1">Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced its third-quarter 2025 financial results on November 6, emphasizing the company’s continuous strategic shift from a direct COVID-19 commercial operation to an R&amp;D-focused company, especially in partnership with Sanofi. For the third quarter, Novavax, Inc. (NASDAQ:NVAX) reported total […]</div>

诺瓦瓦克斯医药

<p>诺瓦瓦克斯医药（NASDAQ:NVAX）公布了 2025 年第三季度财务业绩，强调了从 COVID-19 销售转向专注于研发的战略转变，特别是与赛诺菲的合作。该公司被认为是最被低估的生物科技股票之一，值得投资</p>

诺瓦瓦克斯从新冠疫苗销售转向研发重点，并更新了 2025 年的预测